Multidisciplinary approach on characterizing a mechanochemically activated composite of vinpocetine and crospovidone

Journal of Pharmaceutical Sciences

Volumn 100, Issue 3, 2011, Pages 915-932

  Hasa, Dritan ^a   Voinovich, Dario ^a   Perissutti, Beatrice ^a   Bonifacio, Alois ^a   Grassi, Mario ^a   Franceschinis, Erica ^b   Dall'Acqua, Stefano ^b   Speh, Manuela ^a,c   Plavec, Janez ^a   Invernizzi, Sergio ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c NATIONAL INSTITUTE OF CHEMISTRY   (Slovenia)

Author keywords

Mechanical activation; Micronized crospovidone; Nanocrystals; Oral absorption; Physical characterization; PXRD; Raman spectroscopy imaging; Solid state; SS NMR; Vinpocetine

Indexed keywords

CROSPOVIDONE; NANOCRYSTAL; UNCLASSIFIED DRUG; VIMPOCETIN; VINPOCETINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPOSITE MATERIAL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG SOLUBILITY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; RAMAN SPECTROMETRY; RAT; SOLID STATE; SOLUBILIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION;

EID: 79251560315     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22331     Document Type: Article

References (37)

1. Lorincz C, Szasz K, Kisfaludy L. 1976. The synthesis of ethyl apovincaminate. Arzneim-Forsch Drug Res 26:1907-1908.
2. Weinshaar RE, Bristol JA. 1990. In Comprehensive medicinal chemistry; Hansch C, Ed. Vol. II. Oxford, UK:Pergamon Press, pp 501-514.
3. Ribeiro L, Falcao AC, Patricio JAB, Ferreira DC, Veiga FJB. 2007. Cyclodextrin multicomponent complexation and controlled release delivery strategies to optimize the oral bioavalaibility of vinpocetine. J Pharm Sci 96:2018-2028.
4. Csanda E, Harcos P, Bacsy Z, Berghammer R, Kenez J. 1988. Ten years of experience with Cavinton. Drug Dev Res 14:185-187.
5. Szatmari SZ, Whitehouse PJ. 2003. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 1:CD003119
6. Grandt R, Beitinger R, Schateltenbrand R, Braun W. 1989. Vinpocetine pharmacokinetics in elderly subjects. Arzneimittel-Forschung 39:1599-1602.
7. Szakacs T, Veres Z, Vereczkey L. 2001. In vitro-in vivo correlation of the pharmacokinetics of vinpocetine. Pol J Pharmacol 53:623-628.
8. Kata M, Lukacs M. 1986. Enhancement of solubility of vinpocetine base with γ-cyclodextrin. Pharmazie 41:151-152.
9. Chen Y, Li G, Wu X, Chen Z, Hang J, Qin B, Chen S, Wang R. 2008. Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: Formulation development and in vivo assessment. Biol Pharm Bull 31:118-125.
10. Iosio T, Voinovich D, Grassi M, Pinto J.F, Perissutti B, Zacchigna M, Quintavalle U, Serdoz F. 2008. Bi-layered self-emulsifying pellets prepared by co-extrusion and spheronization: Influence of formulation variables and preliminary study on the in vivo absorption. Eur J Pharm Biopharm 69:686-697.
11. Cui S-X, Nie S-F, Li L, Wang C-G, Pan W-S, Sun J-P. 2009. Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm 35(5): 603-611.
12. Kata M, Selmeczi B. 1987. Increasing the solubility of drugs through cyclodextrin complexation. J Incl Phen 5:39-43.
13. Kata M, Kedvessy G. 1987. Increasing the solubility characteristics of pharmaca with cyclodextrins. Pharm Ind 49(1):98-100.
14. Ribeiro L, Veiga F. 2002. Complexation of vinpocetine with cyclodextrins in the presence or absence of polymers. Binary and ternary complexes preparation and characterization. J Incl Phenom 44:251-256.
15. Ribeiro L, Loftsson T, Ferreira D, Veiga F. 2003a. Investigation and physicochemical characterization of vinpocetine-sulfobutyl ether β-cyclodextrin binary and ternary complexes. Chem Pharm Bull 51:914-922.
16. Ribeiro L, Ferreira D, Veiga F. 2003b. Physicochemical investigation of the effects of water-soluble polymers on vinpocetine complexation with b-cyclodextrin and its sulfobutyl ether derivative in solution and solid state. Eur J Pharm Sci 20:253-266.
17. Ribeiro L, Ferreira DC, Veiga FJB. 2005a. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. J Control Rel 103:325-339.
18. Ribeiro L, Carvalho RA, Ferreira DC, Veiga FJB. 2005b. Multicomponent complex formation between vinpocetine, cyclodextrins, tartaric acid and water-soluble polymers monitored by NMR and solubility studies. Eur J Pharm Sci 24:1-13.
19. Ribeiro L, Carvalho RA, Ferreira DC, Veiga FJB. 2007. In vitro and in vivo studies on the complexes of vinpocetine with hydroxypropyl-β-cyclodextrin. Archiv Pharm Res 30:991-1001.
20. Voinovich D, Perissutti B, Magarotto L, Ceschia D, Guiotto P, Bilia AR. 2009a. Solid state mechanochemical simultaneous activation of the constituents of the Silybum marianum phytocomplex with crosslinked polymers. J Pharm Sci 98:215-228.
21. Voinovich D, Perissutti B, Grassi M, Passerini N, Bigotto A. 2009b. Solid state mechanochemical activation of Silybum marianum dry extract with betacyclodextrins: Characterization and bioavailability of the coground systems. J Pharm Sci 98:4119-4129.
22. Mathieu D, Nony J, Phan-Tan-Luu R. NEMRODW (new efficient technology for research using optimal design) software. LPRAI, Marseille 1999.
23. R Development Core Team. 2009. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Wien, Austria. ISBN 3-900051- 07-0.
24. Coceani N, Magarotto L, Ceschia D, Colombo I, Grassi M. 2010. Melting temperature, enthalpy and solubility dependence on crystal radius. The case of co-ground Nimesulide. J Phys Chem C (submitted).
25. Brun M, Lallemand A, Quinson JF, Eyraud C. 1973. Changement d'etat liquide-solide dans les milieux poreux. II Etude theorique de la solidification d'un condensat capillaire. J Chim Phys 70:979-989.
26. Zhang M, Efremov MY, Schiettekatte F, Olson EA, Kwan AT, Lai SL, Wisleder T, Greene JE, Allen LH. 2000. Size dependent melting point depression of nanostructures: Nanocalorimetric measurements. Phys Rev B 62:10548-10557.
27. Beleites C, Sergo V. 2009. for R (see reference 23)
28. Cadelli G, Zarattini P, Stebel M. 2007. Further refinements of tail artery cannulation in conscious rats, Centro Coordinamento e Sviluppo progetti e Apparecchiature (CSPA). Settore stabulario e sperimentazione animale. Università di Trieste, FELASA-ICLAS Joint Meeting 2007-Villa Erba, Cernobbio (Co).
29. Vlase L, Bodiu B, Leucuta SE. 2005. Pharmacokinetics and comparative bioavailability of two vinpocetine tablet formulations in healthy volunteers by using the metabolite apovincaminic acid as pharmacokinetic parameter. Arzneimittel-Forschung 55:664-668.
30. Faraway JJ. 2004. Linear models with R (Chapman & Hall/CRC Texts in Statistical Science). vol. 63. Taylor & Francis, Boca Raton, FL, 188.
31. Magarotto L, Bertini S, Cosentino C, Torri G. 2001. Characterisation of nimesulide/b- cyclodextrin composite obtained by solid state activation. Mater Sci Forum 360-362:643-648.
32. Taylor LS, Zografi G. 1997. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res 14:1691-1698.
33. Rawlinson CF, Williams CA, Timmins P, Grimsey I. 2007. Polymer-mediated disruption of drug crystallinity. Int J Pharm 336:42-48.
34. Grassi M, Coceani N, Magarotto L, Ceschia D. 2003. Effect of milling time on release kinetics from co-grounded drug-polymer systems. Proceedings of the AAPS Annual Meeting and Exposition, October, Salt Lake City, Utah.
35. Meriani F, Coceani N, Sirotti C, Voinovich D, Grassi M. 2004. In Vitro Nimesulide Absorption from Different Formulations. J Pharm Sci 93:3540-3552.
36. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P, Kinget R. 2000. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci 12:261-269.
37. Shin SC, Oh IJ, Lee YB, Choi HK, Cho CW. 1998. Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. Int J Pharm 175:17-24.